The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [18F] fluorodeoxyglucose PET.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
119 patients underwent [18F]FDG PET/CT and 31 [18F]FDG PET/MRI.
I · Intervention 중재 / 시술
[18F]FDG PET/CT and 31 [18F]FDG PET/MRI
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
In patients with lower cT-status, lobular histology and low-grade estrogen receptor-positive tumour, [18F]FDG PET may be less reliable as staging procedure. Further research is necessary to determine the optimal metabolic threshold for defining a hypometabolic tumour.
[OBJECTIVE] Previous studies reported low [18F] fluorodeoxyglucose ([18F]FDG) PET uptake in estrogen receptor-positive breast tumours, potentially missing detection of distant metastases.
APA
Lenaerts M, van der Voort L, et al. (2026). The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [18F] fluorodeoxyglucose PET.. Nuclear medicine communications. https://doi.org/10.1097/MNM.0000000000002133
MLA
Lenaerts M, et al.. "The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor-positive primary breast cancer on baseline [18F] fluorodeoxyglucose PET.." Nuclear medicine communications, 2026.
PMID
41746946 ↗
Abstract 한글 요약
[OBJECTIVE] Previous studies reported low [18F] fluorodeoxyglucose ([18F]FDG) PET uptake in estrogen receptor-positive breast tumours, potentially missing detection of distant metastases. This study assessed the proportion of estrogen receptor-positive hypometabolic tumours, clinical factors influencing [18F]FDG uptake, and the prognostic impact.
[METHODS] Baseline [18F]FDG PET/computed tomography (CT) and [18F]FDG PET/MRI exams of female patients diagnosed with estrogen receptor-positive locally advanced (cT3-4N0 or cT1-4N+), metastatic, or recurrent breast cancer between 2013-2022 were retrospectively collected. Different thresholds of maximum standardised uptake value (SUVmax) and tumour-to-background ratio (TBR; SUVmax tumour/SUVmax background) were applied to determine the proportion of hypometabolic [18F]FDG PET exams. Logistic regression and survival analysis were performed.
[RESULTS] 119 patients underwent [18F]FDG PET/CT and 31 [18F]FDG PET/MRI. The proportion of hypometabolic tumours for SUVmax thresholds 2.0, 2.5, 3.0, TBR of contralateral breast less than or equal to 1, and TBR of liver less than or equal to 1 was 8.4, 15.1, 21.8, 5.1, and 28.6%, respectively for [18F]FDG PET/CT and 16.1, 19.4, 29.0, 6.9, and 35.5% for [18F]FDG PET/MRI. Clinically tumour status (cT-status), histology type, and tumour grade were associated with the presence of a hypometabolic tumour. No PET-derived variables were associated with recurrence-free survival.
[CONCLUSION] A considerable proportion of estrogen receptor-positive breast tumours showed low SUVmax, indicating potential suboptimal staging on [18F]FDG PET. In patients with lower cT-status, lobular histology and low-grade estrogen receptor-positive tumour, [18F]FDG PET may be less reliable as staging procedure. Further research is necessary to determine the optimal metabolic threshold for defining a hypometabolic tumour.
[METHODS] Baseline [18F]FDG PET/computed tomography (CT) and [18F]FDG PET/MRI exams of female patients diagnosed with estrogen receptor-positive locally advanced (cT3-4N0 or cT1-4N+), metastatic, or recurrent breast cancer between 2013-2022 were retrospectively collected. Different thresholds of maximum standardised uptake value (SUVmax) and tumour-to-background ratio (TBR; SUVmax tumour/SUVmax background) were applied to determine the proportion of hypometabolic [18F]FDG PET exams. Logistic regression and survival analysis were performed.
[RESULTS] 119 patients underwent [18F]FDG PET/CT and 31 [18F]FDG PET/MRI. The proportion of hypometabolic tumours for SUVmax thresholds 2.0, 2.5, 3.0, TBR of contralateral breast less than or equal to 1, and TBR of liver less than or equal to 1 was 8.4, 15.1, 21.8, 5.1, and 28.6%, respectively for [18F]FDG PET/CT and 16.1, 19.4, 29.0, 6.9, and 35.5% for [18F]FDG PET/MRI. Clinically tumour status (cT-status), histology type, and tumour grade were associated with the presence of a hypometabolic tumour. No PET-derived variables were associated with recurrence-free survival.
[CONCLUSION] A considerable proportion of estrogen receptor-positive breast tumours showed low SUVmax, indicating potential suboptimal staging on [18F]FDG PET. In patients with lower cT-status, lobular histology and low-grade estrogen receptor-positive tumour, [18F]FDG PET may be less reliable as staging procedure. Further research is necessary to determine the optimal metabolic threshold for defining a hypometabolic tumour.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Early local immune activation following intra-operative radiotherapy in human breast tissue.
- Overall survival and prognostic factors in young women with breast cancer: a retrospective cohort study from Southern Thailand.
- Age at First Pregnancy, Adult Weight Gain and Postmenopausal Breast Cancer Risk: The PROCAS Study (United Kingdom).
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Structural determinants of glycosaminoglycan oligosaccharides as LL-37 inhibitors in breast cancer.
- Artificial intelligence and breast cancer screening in Serbia: a dual-perspective qualitative study among radiologists and screening-aged women.